Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors

Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors

US Patent 11879013 · Granted Jan 23, 2024

Estimated economic value: $802,401,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Combination therapies with bispecific anti-EGFR/c-met antibodies and third gener2025
Combination therapies with bispecific anti-EGFR/c-met antibodies and third gener2025
Combination therapies with bispecific anti-EGFR/c-met antibodies and third gener2025
EGFR and C-met fibronectin type III domain binding molecules2025
Bispecific EGFR/c-Met antibodies2025
Treatment of patients having c-met exon 14 skipping mutations2025
Treatment of patients having c-met exon 14 skipping mutations2025
Combination therapies and patient stratification with bispecific anti-EGFR/c-Met2025
Proteins comprising HLA-G antigen binding domains and their uses2023
Cyclic dinucleotides as sting agonists2022
Combination therapies and patient stratification with bispecific anti-EGFR/c-Met2022
EGFR and c-Met fibronectin type III domain binding molecules2021